Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12BGS | ISIN: US92242T1016 | Ticker-Symbol: 1V1
Frankfurt
04.11.24
08:17 Uhr
56,00 Euro
0,00
0,00 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
V2X INC Chart 1 Jahr
5-Tage-Chart
V2X INC 5-Tage-Chart
RealtimeGeldBriefZeit
55,5059,0004.11.
PR Newswire
217 Leser
Artikel bewerten:
(1)

V2X, Inc.: V2X Delivers Solid First Quarter Results

First Quarter 2024 Summary

  • Revenue up 7.1% y/y to $1.01 billion
  • Operating income of $30.3 million; adjusted operating income1 of $62.9 million
  • Net income of $1.1 million, up $18.6 million y/y
  • Adjusted EBITDA1 of $69.1 million with a margin1 of 6.8%
  • Diluted EPS of $0.04; Adjusted diluted EPS1 of $0.90
  • Selected to provide technology solutions for threat detection and response to Chemical, Biological, Radiological, & Nuclear hazards
  • Awarded position on U.S. Navy's Global Contingency Services Multiple Award Contract III valued up to $2 billion

2024 Guidance:

  • Reaffirming full-year 2024 guidance

MCLEAN, Va., May 7, 2024 /PRNewswire/ -- V2X, Inc. (NYSE:VVX) announced first quarter 2024 financial results.

"V2X reported a solid start to 2024 with revenue up 7% year-over-year," said Chuck Prow, President and Chief Executive Officer of V2X. "Our leading growth indicators remain strong with a robust backlog of $12.6 billion and a pipeline of nearer-term new business opportunities of $25 billion. V2X continues to advance our transformation to deliver enhanced capabilities in an expanding market. Given our first quarter results and trends we are seeing in our business, we are reaffirming our 2024 guidance."

"We continue to witness growth in the Pacific or INDOPACOM, with our presence in the region proving to be a key channel to support increasing mission requirements," said Mr. Prow. "Revenue in the region was up 7% year-over-year. We continue to expand our scope of services in the region, which includes a new award to deploy an assured and protected private 5G communications solution and enable smart logistics in the Philippines. Additionally, our position in the Middle East or CENTCOM continues to expand with revenue up 22% year-over-year. As the largest services provider to the Department of Defense in the Middle East, V2X stands ready to support our clients mission requirements."

Mr. Prow continued, "V2X remains focused on differentiated operational technologies that fuse the digital and physical aspects of our clients' missions. This differentiation is driving growth and was recently demonstrated through contract awards valued at $75 million to provide technology solutions for threat detection and response to Chemical, Biological, Radiological, and Nuclear (CBRN) hazards. This work expanded from a prototype effort to a new sole source award for the production, upgrade, and fielding of cutting-edge systems at overseas operational locations. Under the contract, V2X is the lead systems integrator for CBRN Support to Command and Control (CSC2) program. CSC2 is the program of record for the integration of CBRN, which will link sensors together to provide integrated situational awareness about potential hazards to inform end user decision making."

Mr. Prow concluded, "I'm pleased to announce that V2X was selected as a prime contractor for the U.S. Navy's Global Contingency Services Multiple Award Contract III (GCSMAC III). The contract is valued at up to $2 billion, was awarded by the Naval Facilities Engineering Command, Pacific in Hawaii, and enables V2X to provide critical support services for a wide range of scenarios, including natural disasters, humanitarian efforts, and military actions. The total contract value for GCSMAC III was increased significantly from the prior iteration, which reached its ceiling value of $900 million. Importantly, V2X was the leading provider of services under the prior iteration of the contract, winning $300 million in task orders."

First Quarter 2024 Results

"V2X reported revenue of $1.0 billion in the quarter, which represents 7.1% year-over-year growth," said Shawn Mural, Senior Vice President and Chief Financial Officer. "Revenue growth in the quarter was achieved through continued expansion of existing business in the Pacific and Middle East regions, as well as new programs. Growth in the Pacific was driven by continued expansion of scope and services, particularly at Kwajalein Atoll. Growth in the Middle East was driven primarily by expansion in Qatar and the ramp up of our longer-term Saudi Aviation Support & Training program."

"For the quarter, the Company reported operating income of $30.3 million and adjusted operating income1 of $62.9 million. Adjusted EBITDA1 was $69.1 million with a margin of 6.8%. First quarter GAAP diluted EPS was $0.04, due primarily to merger and integration related costs, amortization of acquired intangible assets, and interest expense. Adjusted diluted EPS1 for the quarter was $0.90."

"An important attribute of our business is the ability to generate strong cash flow with low capital expenditure requirements. We expect to deliver full-year adjusted net cash provided by operating activities1 of $145 million to $165 million, representing 120% adjusted net income conversion1 at the mid-point. During the quarter, net cash used by operating activities was $57.2 million, in line with our historical pattern and reflective of a receivable delay that collected shortly after the quarter closed. Adjusted net cash used by operating activities1 was $83.5 million, adding back approximately $5.8 million of M&A and integration costs and removing the contribution of the master accounts receivable purchase or MARPA facility of $32.1 million."

"At the end of the quarter, net debt for V2X was $1,173 million. Net leverage ratio1was 3.5x, down from 3.8x at the end of the first quarter 2023. We expect to achieve a net leverage ratio of 3.0x, or below, by the end of 2024."

"Total backlog as of March 29, 2024, was $12.6 billion. Funded backlog was $2.7 billion. Bookings in the quarter were $0.8 billion, resulting in a trailing twelve-month book-to-bill of 1.2x."

Reaffirming 2024 Guidance

Mr. Mural concluded, "We are pleased with the performance across our business and start to the year. Our teams continue to execute, driving expansion on existing operations and phasing in of new programs. As such, the Company is reaffirming its guidance for 2024."

Guidance for 2024 remains as follows:

$ millions, except for per share amounts

2024 Guidance

2024 Mid-Point

Revenue

$4,100


$4,200

$4,150

Adjusted EBITDA1

$300


$315

$308

Adjusted Diluted Earnings Per Share1

$3.85


$4.20

$4.03

Adjusted Net Cash Provided by Operating Activities1

$145


$165

$155

The Company is not providing a quantitative reconciliation with respect to this forward-looking non-GAAP measure in reliance on the "unreasonable efforts" exception set forth in SEC rules because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. For example, unusual, one-time, non-ordinary, or non-recurring costs, which relate to M&A, integration and related activities cannot be reasonably estimated. Forward-looking statements are based upon current expectations and are subject to factors that could cause actual results to differ materially from those suggested here, including those factors set forth in the Safe Harbor Statement below.

First Quarter Conference Call

Management will conduct a conference call with analysts and investors at 8:00 a.m. ET on Tuesday, May 7, 2024. U.S.-based participants may dial in to the conference call at 877-407-3982, while international participants may dial 201-493-6780. A live webcast of the conference call as well as an accompanying slide presentation will be available here: https://app.webinar.net/24war3pJ8n7

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through May 21, 2024, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 13745566.

Presentation slides that will be used in conjunction with the conference call will also be made available online in advance on the "investors" section of the company's website at https://gov2x.com/. V2X recognizes its website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with its obligations under the U.S. Securities and Exchange Commission ("SEC") Regulation FD.

Footnotes:

1 See "Key Performance Indicators and Non-GAAP Financial Measures" for descriptions and reconciliations.

About V2X

V2X builds smart solutions designed to integrate physical and digital infrastructure - by aligning people, actions, and outputs. Our lifecycle solutions improve security, streamline logistics, and enhance readiness.

The Company delivers a comprehensive suite of integrated solutions across the operations and logistics, aerospace, training, and technology markets to national security, defense, civilian and international clients. Our global team of approximately 16,000 employees brings innovation to every point in the mission lifecycle, from preparation to operations, to sustainment, as it tackles the most complex challenges with agility, grit, and dedication.

Contact Information

Investor Contact

Media Contact

Mike Smith, CFA

Angelica Spanos Deoudes

[email protected]

[email protected]

719-637-5773

571-338-5195

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 (the "Act"): Certain material presented herein includes forward-looking statements intended to qualify for the safe harbor from liability established by the Act. These forward-looking statements include, but are not limited to, all the statements and items listed under "2024 Guidance" above and other assumptions contained therein for purposes of such guidance, other statements about our 2024 performance outlook, revenue, contract opportunities, and any discussion of future operating or financial performance.

Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "could," "potential," "continue" or similar terminology. These statements are based on the beliefs and assumptions of the management of the Company based on information currently available to management.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside our management's control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. For a discussion of some of the risks and uncertainties that could cause actual results to differ from such forward-looking statements, see the risks and other factors detailed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC.

We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

V2X, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (UNAUDITED)




Three Months Ended



March 29,


March 31,

(In thousands, except per share data)


2024


2023

Revenue


$ 1,010,564


$ 943,460

Cost of revenue


940,290


864,630

Selling, general, and administrative expenses


39,943


48,251

Operating income


30,331


30,579

Loss on extinguishment of debt


-


(22,052)

Interest expense, net


(27,574)


(31,744)

Other expense, net


(1,633)


-

Income (loss) from operations before income taxes


1,124


(23,217)

Income tax benefit


(20)


(5,737)

Net income (loss)


$ 1,144


$ (17,480)






Earnings (loss) per share





Basic


$ 0.04


$ (0.57)

Diluted


$ 0.04


$ (0.57)

Weighted average common shares outstanding - basic


31,351


30,927

Weighted average common shares outstanding - diluted


31,794


30,927

V2X, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)




March 29,


December 31,

(In thousands, except per share data)


2024


2023

Assets





Current assets





Cash, cash equivalents and restricted cash


$ 35,658


$ 72,651

Receivables


788,490


705,995

Prepaid expenses and other current assets


129,427


96,223

Total current assets


953,575


874,869

Property, plant, and equipment, net


93,362


85,429

Goodwill


1,648,298


1,656,926

Intangible assets, net


389,448


407,530

Right-of-use assets


37,629


41,215

Other non-current assets


17,379


15,931

Total non-current assets


2,186,116


2,207,031

Total Assets


$ 3,139,691


$ 3,081,900

Liabilities and Shareholders' Equity





Current liabilities





Accounts payable


$ 430,600


$ 453,052

Compensation and other employee benefits


139,349


158,088

Short-term debt


15,361


15,361

Other accrued liabilities


267,425


213,700

Total current liabilities


852,735


840,201

Long-term debt, net


1,154,345


1,100,269

Deferred tax liabilities


13,698


11,763

Operating lease liabilities


32,419


34,691

Other non-current liabilities


92,758


104,176

Total non-current liabilities


1,293,220


1,250,899

Total liabilities


2,145,955


2,091,100

Commitments and contingencies (Note 7)





Shareholders' Equity





Preferred stock; $0.01 par value; 10,000,000 shares authorized; No shares issued and outstanding


-


-

Common stock; $0.01 par value; 100,000,000 shares authorized; 31,452,806 and 31,191,628 shares issued and outstanding as of March 29, 2024 and December 31, 2023, respectively


315


312

Additional paid in capital


761,605


762,324

Retained earnings


231,995


230,851

Accumulated other comprehensive loss


(179)


(2,687)

Total shareholders' equity


993,736


990,800

Total Liabilities and Shareholders' Equity


$ 3,139,691


$ 3,081,900

V2X, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)




Three Months Ended



March 29,


March 31,

(In thousands)


2024


2023

Operating activities





Net income (loss)


$ 1,144


$ (17,480)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

Depreciation expense


6,243


5,412

Amortization of intangible assets


22,539


22,606

Loss on disposal of property, plant, and equipment


8


31

Stock-based compensation


5,149


12,872

Deferred taxes


(262)


(6,034)

Amortization of debt issuance costs


2,160


2,513

Loss on extinguishment of debt


-


22,052

Changes in assets and liabilities:





Receivables


(55,363)


(30,649)

Other assets


(23,522)


(9,778)

Accounts payable


(33,715)


(4,115)

Compensation and other employee benefits


(18,607)


(24,182)

Other liabilities


37,000


(11,740)

Net cash used in operating activities


(57,226)


(38,492)

Investing activities





Purchases of capital assets


(7,775)


(9,076)

Proceeds from the disposition of assets


5


-

Acquisitions of businesses


(16,939)


-

Net cash used in investing activities


(24,709)


(9,076)

Financing activities





Proceeds from issuance of long-term debt


-


250,000

Repayments of long-term debt


(3,840)


(421,013)

Proceeds from revolver


375,250


348,750

Repayments of revolver


(319,250)


(163,750)

Proceeds from stock awards and stock options


3


5

Payment of debt issuance costs


-


(7,507)

Prepayment premium on early redemption of debt


-


(1,600)

Payments of employee withholding taxes on share-based compensation


(5,702)


(12,806)

Net cash provided by (used in) financing activities


46,461


(7,921)

Exchange rate effect on cash


(1,519)


1,567

Net change in cash, cash equivalents and restricted cash


(36,993)


(53,922)

Cash, cash equivalents and restricted cash - beginning of period


72,651


116,067

Cash, cash equivalents and restricted cash - end of period


$ 35,658


$ 62,145






Supplemental disclosure of cash flow information:





Interest paid


$ 27,125


$ 29,066

Income taxes paid


$ 1,014


$ 300

Purchase of capital assets on account


$ 410


$ 494

Key Performance Indicators and Non-GAAP Measures

The primary financial performance measures we use to manage our business and monitor results of operations are revenue trends and operating income trends. Management believes that these financial performance measures are the primary drivers for our earnings and net cash from operating activities. Management evaluates its contracts and business performance by focusing on revenue, and operating income. Operating income represents revenue less both cost of revenue and selling, general and administrative (SG&A) expenses. Cost of revenue consists of labor, subcontracting costs, materials, and an allocation of indirect costs, which includes service center transaction costs. SG&A expenses consist of indirect labor costs (including wages and salaries for executives and administrative personnel), bid and proposal expenses and other general and administrative expenses not allocated to cost of revenue.

We manage the nature and amount of costs at the program level, which forms the basis for estimating our total costs and profitability. This is consistent with our approach for managing our business, which begins with management's assessing the bidding opportunity for each contract and then managing contract profitability throughout the performance period.

In addition to the key performance measures discussed above, we consider adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, adjusted EBITDA margin, and adjusted operating cash flow to be useful to management and investors in evaluating our operating performance, and to provide a tool for evaluating our ongoing operations. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment among competing strategic alternatives and initiatives. We provide this information to our investors in our earnings releases, presentations, and other disclosures.

Adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, adjusted EBITDA margin, and adjusted net cash provided by (used in) operating activities, however, are not measures of financial performance under GAAP and should not be considered a substitute for financial measures determined in accordance with GAAP. Definitions and reconciliations of these items are provided below.

  • Adjusted operating income is defined as operating income, adjusted to exclude items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration, and related costs.
  • Adjusted EBITDA is defined as operating income, adjusted to exclude depreciation and amortization of intangible assets, and items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration, and related costs.
  • Adjusted EBITDA margin is defined as adjusted EBITDA divided by revenue.
  • Adjusted net income is defined as net income, adjusted to exclude items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items that impact current results but are not related to our ongoing operations, such as M&A, integration and related costs, amortization of acquired intangible assets, amortization of debt issuance costs, and loss on extinguishment of debt.
  • Adjusted diluted earnings per share is defined as adjusted net income divided by the weighted average diluted common shares outstanding.
  • Cash interest expense, net is defined as interest expense, net adjusted to exclude amortization of debt issuance costs.
  • Adjusted net cash provided by (used in) operating activities or adjusted operating cash flow is defined as net cash provided by (or used in) operating activities adjusted to exclude infrequent non-operating items, such as M&A payments and related costs.
  • Net leverage ratio is defined as net debt (or total debt less unrestricted cash) divided by trailing twelve-month (TTM) bank EBITDA.

Non-GAAP Tables


($K, except per share data)

Three Months Ended


March 29, 2024


March 31, 2023

Revenue

$ 1,010,564


$ 943,460

Net income (loss)

$ 1,144


$ (17,480)

Plus:




Income tax benefit

(20)


(5,737)

Other expense, net

1,633


-

Interest expense, net

27,574


31,744

Loss on extinguishment of debt

-


22,052

Amortization of intangible assets

22,539


22,606

M&A, integration and related costs

9,981


10,767

Adjusted operating income

$ 62,851


$ 63,952

Plus:




Depreciation expense

6,243


5,412

Adjusted EBITDA

$ 69,094


$ 69,364

Adjusted EBITDA margin

6.8 %


7.4 %

Minus:




Cash interest expense, net

25,414


29,231

Income tax expense, as adjusted

7,155


8,580

Depreciation expense

6,243


5,412

Other expense, net

1,633


-

Adjusted net income

$ 28,649


$ 26,141


($K, except per share data)

Three Months Ended


March 29, 2024


March 31, 2023

Diluted earnings (loss) per share

$ 0.04


$ (0.57)

Plus:




M&A, integration and related costs

0.25


0.26

Amortization of intangible assets

0.56


0.54

Amortization of debt issuance costs and Loss on extinguishment of debt

0.05


0.60

Adjusted diluted earnings per share

$ 0.90


$ 0.83





Average shares outstanding




Basic, as reported

31,351


30,927

Diluted, as reported

31,794


30,927

Adjusted diluted

31,794


31,334

SUPPLEMENTAL INFORMATION

Revenue by client branch, contract type, contract relationship, and geographic region for the periods presented below was as follows:

Revenue by Client








Three Months Ended



March 29,


March 31,


(In thousands)


2024

%

2023

%

Army


$ 433,430

43 %

$ 390,503

41 %

Navy


321,384

32 %

292,690

31 %

Air Force


118,569

12 %

129,981

14 %

Other


137,181

13 %

130,286

14 %

Total revenue


$ 1,010,564


$ 943,460


Revenue by Contract Type








Three Months Ended



March 29,


March 31,


(In thousands)


2024

%

2023

%

Cost-plus and cost-reimbursable


$ 604,167

60 %

$ 523,030

55 %

Firm-fixed-price


379,272

38 %

385,112

41 %

Time-and-materials


27,125

2 %

35,318

4 %

Total revenue


$ 1,010,564


$ 943,460






Revenue by Contract Relationship






Three Months Ended



March 29,


March 31,


(In thousands)


2024

%

2023

%

Prime contractor


$ 945,155

94 %

$ 879,179

93 %

Subcontractor


65,409

6 %

64,281

7 %

Total revenue


$ 1,010,564


$ 943,460






Revenue by Geographic Region






Three Months Ended



March 29,


March 31,


(In thousands)


2024

%

2023

%

United States


$ 544,726

54 %

$ 548,770

58 %

Middle East


343,216

34 %

281,121

30 %

Asia


68,802

7 %

64,317

7 %

Europe


53,820

5 %

49,252

5 %

Total revenue


$ 1,010,564


$ 943,460


SOURCE V2X, Inc.

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.